Table 1.
Major current clinical trials of treatment using adoptive cell transfer and oncolytic virus for DMG patients.
| Treatment type | Study | Phase | Status | NCT number |
|---|---|---|---|---|
| Adoptive cell transfer | ||||
| GD2 CAR T cells | GD2 CAR T Cells in DIPG & Spinal DMG | I | Recruiting | NCT04196413 |
| B7H3-specific CAR T cells (SCRI-CARB7H3) | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for DIPG/DMG and Recurrent or Refractory Pediatric Central Nervous System Tumors | I | Recruiting | NCT04185038 |
| (C7R)-GD2.CAR T cells | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | I | Recruiting | NCT04099797 |
| Oncolytic virus | ||||
| DNX2401 (adenovirus) |
Oncolytic Adenovirus, DNX-2401, for Naive DIPG | I | Recruiting | NCT03178032 |
| Wild type Reovirus | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | I | Active, not recruiting |
NCT02444546 |
DIPG = diffuse intrinsic pontine gliomas, DMG = diffuse midline gliomas; CAR T =chimeric antigen receptor T cell